In recent studies, RRM2 was reported to control tumor progression and drug resistance (Gandhi et al., 2020), and was able to regulate the sensitivity of renal cancer cells to Sunitinib and PD-1 Blockade via modulating AKT pathway (Xiong et al., 2021). The gene discussed is RRM2; the disease is neoplasm.